The pharmaceutical care of a multidrug-resistant bacterial infection patient with tigecycline-induced hypofibri-nogenemia
- VernacularTitle:替加环素致多重耐药菌感染患者低纤维蛋白原血症的药学监护
- Author:
Jie LI
1
;
Deqiu ZHU
1
Author Information
1. Dept. of Pharmacy，Tongji Hospital Affiliated to Tongji University，Shanghai 200065，China
- Publication Type:Journal Article
- Keywords:
tigecycline;
pharmaceutical care;
hypofibrinogenemia;
multidrug-resistant bacterial infection
- From:
China Pharmacy
2023;34(8):1010-1013
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for pharmaceutical care of multidrug-resistant bacterial infection patients with tigecycline-induced hypofibrinogenemia and the safe use of tigecycline. METHODS Clinical pharmacists participated in a case of hypofibrinogenemia caused by tigecycline with multidrug-resistant bacterial infection， to determine the correlation of hypofibrinogenemia and tigecycline， and to analyze the risk factors and possible mechanisms of the occurrence of hypofibrinogenemia caused by tigecycline in combination with relevant literature. Clinical pharmacists recommended that physicians discontinued tigecycline and provided human fibrinogen and plasma for correction. RESULTS & CONCLUSIONS Tigecycline was associated with hypofibrinogenemia of the patient. The physician followed the advice of clinical pharmacists and the patient’s fibrinogen level returned to normal. The risk factors of hypofibrinogenemia induced by tigecycline included high dose， long course of treatment， and complication with renal dysfunction. Clinical pharmacists should timely advise physicians to stop taking the drug， and give human fibrinogen and blood product infusion for correction when necessary， so as to avoid the occurrence of serious life- threatening coagulation disorders and ensure the safety of tigecycline use.
